Each patient underwent sequential laser activation in three commonly used modes: fragmentation (low power), dusting (moderate power), and pop-dusting (high power), with temperatures recorded ...

The SOPHIA study retrospectively investigated the first-in-man safety and efficacy in 6 patients with stress urinary incontinence who received the UroActive TM device. Results from the primary ...

Michael Creswell, PGY-3 from the University of Kansas, presented findings from the AUA Medical Student Survey, analyzing changes in the urology residency application process from 2022 to 2024. Against ...

Minh Nguyen, MS2, from the Brody School of Medicine at East Carolina University, presented findings on the evolving trends in pelvic lymph node dissection (PLND) during radical prostatectomy. Her ...

The positive predictive value (PPV) for Bladder EpiCheck was 67.4%, with a negative predictive value (NPV) for both overall and HG disease of 99.6%. WLC demonstrated a PPV of 74%, an NPV of 96.3%, and ...

AUA annual meeting featured a kidney cancer session and a presentation by Dr. Pratik Kanabur discussing a cost-effectiveness analysis of 89 Zr-girentuximab PET-CT (TLX250) to guide management of small ...

(UroToday.com) The American Urological Association's 2025 Annual Meeting, in Las Vegas, Nevada, was host to the Plenary Session on Saturday. Dr. Samir Taneja gave the State-of-the-Art Lecture titled: ...

AUA annual meeting featured a prostate cancer session and a presentation by Dr. Madison Krischak discussing access to prostate cancer clinical trials in the VA and whether veterans with prostate ...

Many patients with prostate cancer rely on caregivers to provide emotional and physical support and help with navigating challenges surrounding medical management. A quantitative survey was conducted ...

Sasanlimab, a subcutaneously administered PD-1 inhibitor, in combination with BCG represents the first potential treatment advancement for BCG-naïve, high-risk non-muscle invasive bladder cancer in ...

In Q1, the company submitted a supplemental Biologics License Application (sBLA) for use of ANKTIVA® plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) ...

• Ultra-low PSA Response (<0.02 ng/mL) with Darolutamide Plus ADT in ARANOTE Correlates with Greatly Improved Clinical Outcomes Interactive Poster Session: IP26-07; April 29, 9:30-11:30 a.m. PDT ...